Protalix BioTherapeutics (PLX) EPS (Basic) (2016 - 2025)
Historic EPS (Basic) for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $0.03.
- Protalix BioTherapeutics' EPS (Basic) fell 2500.0% to $0.03 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.07, marking a year-over-year increase of 14666.67%. This contributed to the annual value of $0.04 for FY2024, which is 6666.67% down from last year.
- Per Protalix BioTherapeutics' latest filing, its EPS (Basic) stood at $0.03 for Q3 2025, which was down 2500.0% from -$0.05 recorded in Q1 2025.
- In the past 5 years, Protalix BioTherapeutics' EPS (Basic) registered a high of $0.29 during Q2 2023, and its lowest value of -$0.25 during Q2 2021.
- For the 5-year period, Protalix BioTherapeutics' EPS (Basic) averaged around -$0.04, with its median value being -$0.06 (2022).
- In the last 5 years, Protalix BioTherapeutics' EPS (Basic) tumbled by 56666.67% in 2021 and then surged by 36363.64% in 2023.
- Quarter analysis of 5 years shows Protalix BioTherapeutics' EPS (Basic) stood at -$0.14 in 2021, then skyrocketed by 50.0% to -$0.07 in 2022, then tumbled by 42.86% to -$0.1 in 2023, then soared by 190.0% to $0.09 in 2024, then plummeted by 66.67% to $0.03 in 2025.
- Its last three reported values are $0.03 in Q3 2025, -$0.05 for Q1 2025, and $0.09 during Q4 2024.